Form 8-K - Current report:
SEC Accession No. 0001213900-24-107409
Filing Date
2024-12-10
Accepted
2024-12-10 16:05:34
Documents
13
Period of Report
2024-12-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0224167-8k_tffpharma.htm   iXBRL 8-K 25950
  Complete submission text file 0001213900-24-107409.txt   200948

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tffp-20241204.xsd EX-101.SCH 3018
3 XBRL LABEL FILE tffp-20241204_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tffp-20241204_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0224167-8k_tffpharma_htm.xml XML 3799
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

EIN.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 241538487
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)